Tech Company Financing Transactions
Dioseve Funding Round
Dioseve, operating out of Tokyo, secured $3 million from ANRI and Coral Capital Management.
Transaction Overview
Company Name
Announced On
8/23/2022
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Undisclosed
Investors
ANRI (Lead Investor)
Proceeds Purpose
The new funding will enable Dioseve to hire more people and accelerate its research and development. It aims to establish proof of concept by having mice give birth with DIOLs-produced oocytes, and recently established a new lab in Tokyo and hired an iPS specialist.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
2-3-11 Nihonbashihoncho, Chuo-ku
Tokyo, 103-0023
Japan
Tokyo, 103-0023
Japan
Phone
Undisclosed
Website
Email Address
Overview
Our revolutionary technology, DIO (Directly Induced Oocyte), is capable of producing an extremely large yield of fertilizable egg cells at a minimal cost in a fraction of the time. We aim to create state-of-the-art solutions to a myriad of problems surrounding pregnancy, including infertility as a result of age and hereditary disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kazuma Kishida
Chief Scientific Officer
Nobuhiko Hamazaki
Browse more venture capital transactions:
Prev: 8/23/2022: 28 by Evie venture capital transaction
Next: 8/23/2022: Mojocare venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs